RxDoctor Payments Data

Brian Harris, MD

Internal Medicine · Omaha, NENPI 1275892002

Payments from drug & device makers

$3,675in general payments, 2019–2025

Across 235 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$462
  • AbbVie$429
  • Novo Nordisk$306
  • Astellas Pharma US Inc$263
  • Lilly USA, LLC$251
  • AstraZeneca$251
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,675100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,675 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$148,915
Medicare patients
363
Services billed
2,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$94,964
JardianceEmpagliflozin59$56,477
OzempicSemaglutide28$33,213
MounjaroTirzepatide29$28,873
FarxigaDapagliflozin Propanediol39$20,694
JanuviaSitagliptin Phosphate14$20,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,393
XareltoRivaroxaban17$16,703
MyrbetriqMirabegron16$8,719
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,198
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,040
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$5,961
GemtesaVibegron16$5,306
Advair HfaFluticasone Propion/Salmeterol11$4,814
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$208$96,393121 claims
Boehringer IngelheimJardiance$115$56,47759 claims
Novo NordiskOzempic$306$33,21328 claims
Lilly USA, LLCMounjaro$251$28,87329 claims
AstraZenecaFarxiga, Breztri Aerosphere$251$26,65651 claims
GSKTrelegy Ellipta, Anoro Ellipta$28$24,59133 claims
MerckJanuvia$30$20,28814 claims
Johnson & JohnsonXarelto$66$16,70317 claims
Astellas Pharma US IncMyrbetriq$263$8,71916 claims
Sumitomo Pharma America, Inc.Gemtesa$48$5,30616 claims
AbbVieSynthroid$429$1,18520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →